Patterns of Neurological Adverse Events Among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors
Immunotherapy · 2024-04 · 16 (6) · 381-390
DOI: 10.2217/imt-2023-0273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, online erschienen am 10.01.2024. Verfasst von John C Hunting und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Themen: Patientensicherheit
Abstract (Originalsprache)
Aim
Neurological adverse events (NAEs) are infrequent immune checkpoint inhibitor (ICI) outcomes poorly characterized in extant research, complicating their clinical management.
Methods
This study characterized the frequency, severity, patterning and timing of NAEs using a large retrospective registry, including all patients who received at least one dose of an ICI from 2/1/2011-4/7/2022 within our health network.
Results
Among 3137 patients, there were 54 NAEs (1.72% any grade; 0.8% grade 3-4). Most NAEs were peripheral (57.4%) versus central (42.6%). Melanoma and renal cell carcinoma were significantly associated with NAEs.
Conclusion
The incidence of NAEs was rare though higher than many prior case estimates; the timing was consistent with other AEs. NAEs frequently occurred in tumor types known to favor brain metastases. Immune checkpoint inhibitors are new drugs for cancer. They boost your body's defenses to fight cancer cells. These drugs can be used alone or with other cancer treatments. Most people are okay with these medicines, but some might have problems in different parts of the body. This can be tricky to figure out. Rarely, there can be issues in the brain or nerves. These side effects are rare, happening in about 2 in every 100 people who use the drugs. They are more common in certain cancers like melanoma and kidney cancer. As doctors learn more about these side effects, they can better predict, treat, and prevent them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
- Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
- Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
ORCID-Profile: John C Hunting
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Hunting, J. C., Faucheux, A. T., Price, S. N., Elko, C. A., Quattlebaum, A., Bloomer, C., Olson, E., Petty, W. J., & Lycan, T. W. (2024). Patterns of Neurological Adverse Events Among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors. Immunotherapy, 16(6), 381-390. https://doi.org/10.2217/imt-2023-0273
Vancouver
Hunting JC, Faucheux AT, Price SN, Elko CA, Quattlebaum A, Bloomer C, et al. Patterns of Neurological Adverse Events Among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors. Immunotherapy. 2024;16(6):381-390. doi:10.2217/imt-2023-0273
BibTeX
@article{Hunting2024,
author = {Hunting, John C and Faucheux, Andrew T and Price, Sarah N and Elko, Catherine A and Quattlebaum, Alexander and Bloomer, Chance and Olson, Eric and Petty, William J and Lycan, Thomas W},
title = {Patterns of Neurological Adverse Events Among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors},
journal = {Immunotherapy},
year = {2024},
volume = {16},
number = {6},
pages = {381--390},
doi = {10.2217/imt-2023-0273}
}
EUVIMED